Literature DB >> 23824179

Cutaneous side effects of vemurafenib: a case report and discussion.

Sofia M Shea1, Katherine Boyd, James Patterson.   

Abstract

In 2011, the FDA approved the drug vemurafenib, a potent kinase inhibitor with specificity for the BRAF V600E mutation, for the treatment of metastatic melanoma. While this drug is otherwise well-tolerated, many patients develop cutaneous toxicities. This report demonstrates multiple cutaneous toxicities in a patient while undergoing treatment with vemurafenib.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23824179     DOI： 10.1007/s10354-013-0217-1

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  19 in total

1.  Ultraviolet A and photosensitivity during vemurafenib therapy.

Authors:  Reinhard Dummer; Jeannine Rinderknecht; Simone M Goldinger
Journal:  N Engl J Med       Date:  2012-02-02       Impact factor: 91.245

2.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

Authors:  M R Middleton; J J Grob; N Aaronson; G Fierlbeck; W Tilgen; S Seiter; M Gore; S Aamdal; J Cebon; A Coates; B Dreno; M Henz; D Schadendorf; A Kapp; J Weiss; U Fraass; P Statkevich; M Muller; N Thatcher
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

Review 4.  RAF inhibition and induction of cutaneous squamous cell carcinoma.

Authors:  Caroline Robert; Jean-Philippe Arnault; Christine Mateus
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

5.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

Authors:  P B Chapman; L H Einhorn; M L Meyers; S Saxman; A N Destro; K S Panageas; C B Begg; S S Agarwala; L M Schuchter; M S Ernstoff; A N Houghton; J M Kirkwood
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.

Authors:  Jean Philippe Arnault; Christine Mateus; Bernard Escudier; Gorana Tomasic; Janine Wechsler; Emilie Hollville; Jean-Charles Soria; David Malka; Alain Sarasin; Magalie Larcher; Jocelyne André; Nyam Kamsu-Kom; Lise Boussemart; Ludovic Lacroix; Alain Spatz; Alexander M Eggermont; Sabine Druillennec; Stephan Vagner; Alain Eychène; Nicolas Dumaz; Caroline Robert
Journal:  Clin Cancer Res       Date:  2011-11-17       Impact factor: 12.531

7.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Authors:  Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-28       Impact factor: 11.205

8.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

Review 9.  Dermatological adverse events from BRAF inhibitors: a growing problem.

Authors:  Viswanath Reddy Belum; Alyssa Fischer; Jennifer Nam Choi; Mario E Lacouture
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.